Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
12
Recruiting, any sponsor type, condition "neovascular wet age-related macular degeneration"
By trial status
The same filters, counted in each status. Pick one to switch.
12 trials
Showing 1 to 12, recently updated first.
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07496567 · 960 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 31, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Encino, California · 121 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07440225 · 960 participants (planned) · Start Mar 27, 2026 · Primary completion Jun 30, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Springdale, Arkansas · 148 sites in all
AiViva BioPharma, Inc.Industry
NCT07557121 · 35 participants (planned) · Start Jul 1, 2026 · Primary completion Jun 30, 2027
Drug: AIV007; EYLEA® (aflibercept) Injection 2 mg (0.05mL) · For: Neovascular (Wet) Age-Related Macular Degeneration
Sites: Torrance, California; McAllen, Texas
- Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPivotal-lookingRecruiting
4D Molecular TherapeuticsIndustry
NCT07064759 · 480 participants (planned) · Start Jul 22, 2025 · Primary completion Nov 2027
Drug: 4D-150 IVT (3E10 vg/eye); EYLEA® (aflibercept) Injection 2 mg (0.05mL) · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Scottsdale, Arizona; Sun City, Arizona; Tucson, Arizona · 126 sites in all
- Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular DegenerationRecruiting
Eyconis INC.Academic, hospital or other
NCT07587515 · 30 participants (planned) · Start May 19, 2026 · Primary completion May 2028
Drug: EYC-0305 · For: Neovascular (Wet) Age-Related Macular Degeneration
Sites: Beverly Hills, California; Modesto, California; Wake Forest, North Carolina · 7 sites in all
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)Pivotal-lookingRecruiting
Adverum Biotechnologies, Inc.Industry
NCT07482176 · 534 participants (planned) · Start Mar 16, 2026 · Primary completion Nov 15, 2027
Drug: Aflibercept · For: Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 79 sites in all
- 4D-150 in Patients With Neovascular (Wet) Age-Related Macular DegenerationPivotal-lookingRecruiting
4D Molecular TherapeuticsIndustry
NCT05197270 · 215 participants (planned) · Start Dec 9, 2021 · Primary completion Mar 2027
Drug: 4D-150 IVT; Aflibercept IVT · For: Neovascular (Wet) Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Oxnard, California; Sacramento, California · 26 sites in all
West China HospitalAcademic, hospital or other
NCT07776522 · 50 participants (planned) · Start Aug 31, 2026 · Primary completion Aug 15, 2027
Drug: JWK001; Aflibercept (2.0 mg) · For: Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Sites: Beijing, China; Jilin City, China; Chongqing, China · 16 sites in all
- Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)Pivotal-lookingRecruiting
Innostellar Biotherapeutics Co.,LtdIndustry
NCT07317934 · 388 participants (planned) · Start Jan 14, 2026 · Primary completion Mar 2028
Drug: Aflibercept · For: Neovascular Age-Related Macular Degeneration (nAMD); Wet AMD
Sites: Hefei, China; Beijing, China; Chongqing, China · 36 sites in all
- Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal VasculopathyPivotal-lookingRecruiting
SANGMYUNG innovationIndustry
NCT07695207 · 266 participants (planned) · Start Sep 15, 2025 · Primary completion Dec 2027
Drug: SMZ1; SMZ1 Placebo · For: Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Sites: Seoul, South Korea
Intra-IMMUSG Pte LtdIndustry
NCT07547228 · 15 participants (planned) · Start Oct 11, 2025 · Primary completion Feb 7, 2027
Drug: PRL3-ZUMAB · For: Neovascular Age Related Macular Degeneration
Sites: Singapore, Singapore
- Treatment of Neovascular AMD: Artificial Intelligence in Real-world SettingPivotal-lookingRecruiting
Medical University of ViennaAcademic, hospital or other
NCT05093374 · 290 participants (planned) · Start Mar 1, 2021 · Primary completion Dec 31, 2025
Drug: anti-VEGF agent; anti-VEGF agent · For: Exudative Macular Degeneration
Sites: Vienna, Austria
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.